BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Bioresponsive Drug Delivery
DTSTART:20190719T160000
DTEND:20190719T170000
DTSTAMP:20260405T193207Z
UID:7b56fa18d09c18d1bf102b69913e91daa01a143bb1dea76bb9e377fa
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Zhen Gu\, University of California\, Los Angeles\, CA (U
 SA)\nBIOENGINEERING SEMINAR\n\nAbstract:\nSpurred by recent advances in ma
 terials chemistry\, molecular pharmaceutics and nanobiotechnology\, stimul
 i-responsive “smart” systems offer opportunities for precisely deliver
 ing drugs in dose-\, spatial- and temporal-controlled manners. In this tal
 k\, I will discuss our ongoing efforts in developing physiological signal-
 triggered bioinspired drug delivery systems. I will first present the gluc
 ose-responsive synthetic systems for biomimetic delivery of insulin for di
 abetes treatment. Bioresponsive microneedle patches and vesicle fusion-med
 iated synthetic beta cells will be emphasized. I will further discuss the 
 local and targeted delivery of immunomodulatory therapeutics for enhanced 
 cancer therapy. Our latest study utilizing platelets\, cell conjugates and
  gels for delivery of immune checkpoint inhibitors will be specifically in
 troduced.\n\nBio:\nDr. Zhen Gu is a Full Professor in the Department of Bi
 oengineering and Director of the NIH Biotechnology Training in Biomedical 
 Sciences and Engineering Program at the University of California\, Los Ang
 eles (UCLA). Dr. Gu received his B.S. degree in Chemistry and M.S. degree 
 in Polymer Chemistry and Physics from Nanjing University. In 2010\, he obt
 ained Ph.D. at UCLA\, under the guidance of Dr. Yi Tang in the Department 
 of Chemical and Biomolecular Engineering. He was a Postdoctoral Associate 
 working with Dr. Robert Langer at MIT and Harvard Medical School during 20
 10 to 2012. Before he moved to UCLA in 2018\, he had been appointed as a J
 ackson Family Distinguished Professor in the Joint Department of Biomedica
 l Engineering at the University of North Carolina at Chapel Hill and North
  Carolina State University. Dr. Gu’s group studies controlled drug deliv
 ery\, bio-inspired materials and nanobiotechnology\, especially for cancer
  and diabetes treatment. He has published over 170 research papers and app
 lied over 60 patents. He is a co-founder of five start-up companies. He se
 rves as an Associate Editor for Nano Research and Science Advances. He is 
 also an Inaugural Chair of the Bioinspired and Biomimetic Delivery (BBD) F
 ocus Group in the Controlled Release Society (CRS). Dr. Gu is the recipien
 t of the Sloan Research Fellowship (2016)\, Biomaterials Science Lecturesh
 ip Award (2018)\, Young Investigator Award of CRS (2017)\, Alcoa Foundatio
 n Research Achievement Award (2017)\, Pathway Award of the American Diabet
 es Association (ADA\, 2015) and Young Innovator Award in Cellular and Mole
 cular Engineering of the Biomedical Engineering Society (BMES\, 2015). MIT
  Technology Review listed him in 2015 as one of the global top innovators 
 under the age of 35 (TR35). He was elected to the College of Fellows of th
 e American Institute for Medical and Biological Engineering (AIMBE) in 201
 9.\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR